A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

Solitaire X Revascularization Device is Launched by Medtronic in the USA

System Offers New Options for Improving Outcomes in Treating Stroke; World`s Second-Leading Cause of Death, Third-Leading Cause of Disability

Solitaire X Revascularization Device, Medtronic has announced launch of their device in the U.S. as well as its first use in patients for the treatment of acute ischemic stroke. For ten years, the industry-leading Solitaire(TM) Revascularization Device has enabled physicians in helping patients have a better chance at recovering from stroke.

The Solitaire X Revascularization Device is a 4th generation device featuring an optimized delivery system for improved efficiency – while retaining the technical features that have made the Solitaire family of revascularization devices clinically proven and highly effective. In addition, Medtronic introduces Phenom(TM) 21 Catheter, a 160cm length microcatheter for the delivery of all sizes of Solitaire X.

The Solitaire X device mechanically removes blood clots from blocked vessels in the brain to restore blood flow in patients suffering an acute ischemic stroke with large vessel occlusion. When combined with Phenom 21, Solitaire X provides a low clot crossing profile, with smooth delivery to occlusions in distal vessels as small as 2.0mm. This compatible system reinforces Medtronic’s commitment to the fight against stroke.

“Medtronic continues to deliver technological innovations to advance stroke treatment. As a long-time Solitaire user, I am impressed with the ease of the Solitaire X delivery,” said Dr. Reza Jahan, professor of radiology and neurosurgery at UCLA. “I find that Solitaire X 6×40 device combined with Phenom 21 catheter provides smooth navigation especially when working with complicated anatomy.”

Globally, stroke is the second leading cause of death, killing nearly 6 million people each year. It is also the third leading cause of disability.1 In the United States, approximately 795,000 people suffer a stroke annually, and it is the leading cause of serious, long-term disability. In fact, in the U.S. a stroke occurs every 40 seconds,2 and every four minutes someone dies of a stroke.3

“Our commitment to enable physicians to improve outcomes for stroke patients worldwide will always be our motivation,” said Stacey Pugh, vice president and general manager of Medtronic’s Neurovascular business, which is part of the Restorative Therapies Group at Medtronic. “The net result of that commitment is the launch of a 4th generation device – Solitaire X – which marks 10 years of innovation in stroke therapy.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy